non targeting dsrna Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Thermo Fisher megascript rnai kit
    Megascript Rnai Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 4026 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/megascript rnai kit/product/Thermo Fisher
    Average 99 stars, based on 4026 article reviews
    Price from $9.99 to $1999.99
    megascript rnai kit - by Bioz Stars, 2020-07
    99/100 stars
      Buy from Supplier

    88
    ALZA non targeting dsrna
    Non Targeting Dsrna, supplied by ALZA, used in various techniques. Bioz Stars score: 88/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non targeting dsrna/product/ALZA
    Average 88 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    non targeting dsrna - by Bioz Stars, 2020-07
    88/100 stars
      Buy from Supplier

    88
    Horizon Discovery non targeting dsrna
    Non Targeting Dsrna, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 88/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non targeting dsrna/product/Horizon Discovery
    Average 88 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    non targeting dsrna - by Bioz Stars, 2020-07
    88/100 stars
      Buy from Supplier

    88
    Thermo Fisher non targeting dsrna
    Non Targeting Dsrna, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non targeting dsrna/product/Thermo Fisher
    Average 88 stars, based on 7 article reviews
    Price from $9.99 to $1999.99
    non targeting dsrna - by Bioz Stars, 2020-07
    88/100 stars
      Buy from Supplier

    85
    Horizon Discovery i fect encapsulated non targeting dsrna
    A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of <t>i-Fect</t> encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting <t>dsRNA</t> (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.
    I Fect Encapsulated Non Targeting Dsrna, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 85/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/i fect encapsulated non targeting dsrna/product/Horizon Discovery
    Average 85 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    i fect encapsulated non targeting dsrna - by Bioz Stars, 2020-07
    85/100 stars
      Buy from Supplier

    85
    Thermo Fisher stability enhanced non targeting dsrna control oligonucleotide
    A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of <t>i-Fect</t> encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting <t>dsRNA</t> (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.
    Stability Enhanced Non Targeting Dsrna Control Oligonucleotide, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stability enhanced non targeting dsrna control oligonucleotide/product/Thermo Fisher
    Average 85 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    stability enhanced non targeting dsrna control oligonucleotide - by Bioz Stars, 2020-07
    85/100 stars
      Buy from Supplier

    85
    Thermo Fisher non targeting control dsrna
    A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of <t>i-Fect</t> encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting <t>dsRNA</t> (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.
    Non Targeting Control Dsrna, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non targeting control dsrna/product/Thermo Fisher
    Average 85 stars, based on 13 article reviews
    Price from $9.99 to $1999.99
    non targeting control dsrna - by Bioz Stars, 2020-07
    85/100 stars
      Buy from Supplier

    85
    Horizon Discovery human double stranded rna dependent protein kinase pkr mrna
    A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of <t>i-Fect</t> encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting <t>dsRNA</t> (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.
    Human Double Stranded Rna Dependent Protein Kinase Pkr Mrna, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 85/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human double stranded rna dependent protein kinase pkr mrna/product/Horizon Discovery
    Average 85 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    human double stranded rna dependent protein kinase pkr mrna - by Bioz Stars, 2020-07
    85/100 stars
      Buy from Supplier

    Image Search Results


    A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of i-Fect encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting dsRNA (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.

    Journal: European journal of pharmacology

    Article Title: Intrathecal Raf-1-selective siRNA attenuates sustained morphinemediated thermal hyperalgesia

    doi: 10.1016/j.ejphar.2008.10.033

    Figure Lengend Snippet: A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of i-Fect encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting dsRNA (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.

    Article Snippet: After recovery from the surgery (5–7 days), the animals received intrathecal injections (2ug siRNA/10 ul/rat) of either a lipid encapsulated Raf-1-selective siRNA mixture (Smart pool siRNA, Dharmacon Inc; Chicago, IL, Cat # L-087699-00 ) (Raf-1 siRNA groups) or i-Fect encapsulated non-targeting dsRNA (Dharmacon, # D-001810-01-20 ) (control mismatch siRNA groups) or the transfection lipid alone, once daily, for 3 days, as described earlier ( ).

    Techniques: Transfection